Subsequently, some studies found that ICSs may lead to the down-regulation of ACE2 in the lungs by mediating the inhibition of type I interferon [76], which is of great significance for reducing the susceptibility of patients to COVID-19 and alleviating clinical symptoms. This evidence concerns the gene ACE2 and COVID-19.